¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Early Growth Response Protein 3"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® protein ÇÑ±Û ´Ü¹éÁú
¼³¸í   
  Åº¼Ò, ¼ö¼Ò, »ê¼Ò, Áú¼Ò, È²À» ÇÔÀ¯Çϰí Àִ À¯±âÈ­ÇÕ¹°·Î, ¸ðµç ¼¼Æ÷ÀÇ ¿øÇüÁúÀ» ÀÌ·ç°í Àִ ±âº» ±¸¼º¹°ÁúÀÌ´Ù. ´Ü¹éÁúÀº ±× ´ÜÀ§ÀΠ¾Æ¹Ì³ë»êµéÀÌ ÆéƼµå°áÇÕ¿¡ ÀÇÇØ °áÇյǾî ÀÖÀ¸¸ç, º¸Åë 20°³ÀÇ ¾Æ¹Ì³ë»êµéÀÌ ´Ù¸¥ ¼ø¼­¿Í Á¶¼ºÀ» °¡Áö°í ¹è¿­µÇ¾î, µ¶Æ¯ÇÑ ÇϳªÀÇ ´Ü¹éÁúÀ» Çü¼ºÇϰԠµÈ´Ù.
¿µ¹® growth hormone ÇÑ±Û ¼ºÀåÈ£¸£¸ó
¼³¸í   
  ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼­ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀڱصǸ砼Ҹ¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼­ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŰ¸ç Æ¯È÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇϴ °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼­ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇ̵Ǹ頼ºÀåºÎÁøÀÌ ¿Â´Ù.
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early ambulation
    Á¶±âº¸Çà
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early neonatal mortality rate
    Á¶±â½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â¼ö¿ëüÀüÀ§, Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early syphilis
    Ãʱâ¸Åµ¶
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • antiviral protein
    Ç×¹ÙÀÌ·¯½º´Ü¹éÁú
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early ambulation
    Á¶±âº¸Çà
  • protein binding
    ´Ü¹é°áÇÕ
  • protein-losing enteropathy
    ´Ü¹é¼Ò½ÇâÀÚº´Áõ
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • adherence protein
    ºÎÂø´Ü¹é
  • reserve protein
    ÀúÀå´Ü¹é
  • split-timed urine protein
    ½Ã°£´ëº°¿ä´Ü¹éÁ¤·®
  • structural protein
    ±¸Á¶´Ü¹é, ±¸Á¶´Ü¹éÁú
  • growth factor
    ¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early reaction
    Á¶±â¹ÝÀÀ
  • early syphilis
    Ãʱâ¸Åµ¶, Á¶±â¸Åµ¶
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
  • adherence protein
    ºÎÂø´Ü¹é
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • protein binding
    ´Ü¹é°áÇÕ
  • carrier protein
    ¿î¹Ý´Ü¹é, ¿î¹Ý´Ü¹éÁú
  • catabolite activating protein
    ÀÌÈ­»ê¹°È°¼ºÈ­´Ü¹é
  • coat protein
    ¿ÜÇǴܹé
  • competitive protein binding radioassay
    °æÇմܹé°áÇÕ¹æ»çÃøÁ¤(¹ý)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immediate early gene
    Á¶±â ¹ßÇö À¯ÀüÀÚ
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • BERA =Brainstem Evoked Response Audiometry
    ³ú°£À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • Fast response
    ±Þ¼Ó(ÐááÜ)¹ÝÀÀ(Úãëë)
  • Inflammatory response
    ¿°Áõ¹ÝÀÀ(æúñøÚãëë)
  • Lewis triple response
    ·çÀ̽º »ïÁß ¹ÝÀÀ
  • MAC-BAR(minimum alveolar concentration-blockade of autonomic response)
    ÀÚÀ²½Å°æ¾ïÁ¦ ÃÖ¼ÒÆóÆ÷³»³óµµ
  • allergic response
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • analytical response detection
    ºÐ¼®¹ÝÀÀ°¨Áö
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • approximate response
    ±Ù»ç¹ÝÀÀ
  • arousal reaction=arousal response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early protein
    ÃʱâÃâÇö´Ü¹éÁú
  • growth arrest line (=growth recovery line)
    ¼ºÀå Áö¿¬¼±
  • amblyopia of early arrest
    Á¶±âÁ¤Áö¾à½Ã
  • early
    Á¶±â
  • early ambulation
    Á¶±â¿îµ¿½ÃÀÛ.
  • early ambulation
    Á¶±â¿îµ¿
  • early antigen
    ÃʱâÃâÇöÇ׿ø
  • early antigen
    Á¶±â Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï(ðÄÑ¢äß).
  • early cancer
    Á¶±â¾Ï(Á¶±â¾Ï).
  • early delivery
    Á¶±âºÐ¸¸.
  • early diagnosis
    Á¶±âÁø´Ü.
  • early diastolic murmur =protodiastolic m.
    Á¶±âÈ®ÀåÃʱâÀâÀ½(ðÄÑ¢üªíåôøÑ¢íÚëå).
  • early diastolic murmur =protodiastolic m.
    È®ÀåÃʱâ½ÉÀâÀ½.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Protein granule
    ´Ü¹éÁú°ú¸³
    [¿¾ ¿ë¾î] ´Ü¹éÁú°ú¸³
  • Appositional growth
    µ¡ºÙÀ̼ºÀå
    [¿¾ ¿ë¾î] ÷°¡¼ºÀå
  • Abnormal growth
    ºñÁ¤»ó¼ºÀå
    [¿¾ ¿ë¾î] ºñÁ¤»ó¼ºÀå
  • Interstitial growth
    »çÀÌÁú¼ºÀå
    [¿¾ ¿ë¾î] °£Áú¼ºÀå
  • Growth abnormality
    ¼ºÀåÀÌ»ó
    [¿¾ ¿ë¾î] ¼ºÀåÀÌ»ó
  • Growth defect
    ¼ºÀå°áÇÔ
    [¿¾ ¿ë¾î] ¼ºÀå°áÇÔ
  • Growth cone
    ¼ºÀå¿ø»Ô
    [¿¾ ¿ë¾î] ¼ºÀå¿øÃß
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • circumsporozoite protein (CSP)
    Æ÷ÀÚ¼Òü¸·´Ü¹éÁú
  • protein layer
    ´Ü¹éÁúÃþ
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early protein
    Á¶±â ´Ü¹éÁú (ðÄÑ¢Ó±ÛÜòõ)
  • early enzyme
    Á¶±â È¿¼Ò(ðÄÑ¢ý£áÈ)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • early RNA
    Á¶±â(ðÄÑ¢) RNA
  • immediate early RNA
    ÃÖÁ¶±â(õÌðÄÑ¢) RNA
  • very early RNA
    ÃÊÁ¶±â(õ±ðÄÑ¢) RNA
  • adaptive response
    ÀûÀÀÀû ´ëÀÀ(îêëëîÜÓßëë)
  • anamnestic response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ(ì£ó­Øóæ¹Úãëë)
  • anaphylactic response
    ¾Æ³ªÇʶô½Ã½º ´ëÀÀ(Óßëë)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • autoimmune response
    ÀÚ°¡¸é¿ª´ëÀÀ (í»Ê«Øóæ¹Óßëë)
  • biological response modifier
    »ý¹°ÇÐÀû ´ëÀÀ¼ö½ÄÀÚ(ßæÚªùÊîÜÓßëëáóãÞí­)
  • booster response
    ºÎ½ºÅÍ ´ëÀÀ(Óßëë)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • heat shock response
    ¿­(æð)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early diagnosis
    Á¶±âÁø´Ü
  • early gastric cancer
    Á¶±âÀ§¾Ï
  • response
    ¹ÝÀÀ, ÀÀ´äÀÇ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • growth
    ¼ºÀå
  • growth abnormality
    ¹ßÀ°ÀÌ»ó
  • growth and development
    ¼ºÀå°ú ¹ßÀ°
  • growth arrest line
    ¼ºÀåÁö¿¬¼±
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth line
    ¼ºÀå¼±
  • growth retardation
    ¼ºÀåÁö¿¬
  • Bence-Jones protein
    º¥½º-Á¸½º´Ü¹é
  • C-reactive protein
    C-¹ÝÀÀ¼º´Ü¹éÁú
  • high protein diet
    °í´Ü¹é½ÄÀÌ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
AER abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
EGR early growth response; erythema gyratum repens
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Egr Early Growth Response
Egr-1 Early Growth Response factor 1
EGR1 early growth response 1 gene
Egr-1 Early growth response-1
EAR Early asthmatic response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • amblyopia of early arrest
    Á¶±â Á¤Áö ¾à½Ã
  • early ambulation
    Á¶±â ¿îµ¿ ½ÃÀÛ
  • early assessment
    ÃÊ±â Æò°¡
  • early childhood
    Ãʱ⠾Ƶ¿±â
    ¸¸ 1-6¼¼ ±îÁöÀÇ ½Ã±â.
  • early clinical symptom
    Ãʱâ ÀÓ»ó Áõ»ó
  • early closing clicking joint noise
    Æó±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ ÈĹæ ȰÁÖ ¿îµ¿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
  • early diagnosis
    Á¶±â Áø´Ü
    º´ÀÇ ÁøÇà¿¡ ¾Õ¼­ Áø´ÜÇÏ¿© ´ëÃ¥À» ¼¼¿ò, ¿ÏÀü Ä¡À¯ ±â´ë.
  • early distal tubule
    Ãʱ⠿øÀ§ ¼¼´¢°ü
  • early gestation
    ÀӽŠÃʱâ
  • early melanoma
    Ãʱâ Èæ»öÁ¾
    ¸á¶ó´Ñ ¼¼Æ÷ÀÇ ¾Ç¼º Á¾¾ç¿¡ Ãʱ⠴ܰè. Á¾Á¾ ¾ç¼º ¸ð¹ÝÀ¸·Î ¿ÀÇØµÈ´Ù. ±¸°­¿¡¼­ °¡Àå ÈçÇÑ Èæ»öÁ¾Àº Ç¥Ãþ È®À强 Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾, ¸»´ÜÈæ»öÁ¾À¸·Î ³ª´µ¾îÁø´Ù. ¿¹Èİ¡ ³ª»Ú´Ù.
  • early nodular melanoma
    Ãʱ⠼ҰáÀý¼º Èæ»öÁ¾
  • early opening clicking joint noise
    °³±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ Àü¹æ ȰÁֿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
  • early petechiae
    Ãʱâ Á¡»ó ÃâÇ÷
  • early postprandial postgastrectomy syndrome
    Á¶±â ½ÄÈļº À§ ÀýÁ¦ ÈÄ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
epidermal growth factor receptor protein-tyrosine kinase <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
adenovirus early proteins <molecular biology, protein, virology> Proteins encoded by adenoviruses that are synthesised prior to, and in the absence of, viral DNA replication.
The proteins are involved in both positive and negative regulation of expression in viral and cellular genes, and also affect the stability of viral mRNA. Some are also involved in oncogenic transformation.
(12 Dec 1998)
genes, immediate-early Genes that show rapid and transient expression in the absence of de novo protein synthesis. The term was originally used exclusively for viral genes where immediate-early referred to transcription immediately following virus integration into the host cell. It is also used to describe cellular genes which are expressed immediately after resting cells are stimulated by extracellular signals such as growth factors and neurotransmitters.
(12 Dec 1998)
history of medicine, early modern The period of the history of medicine from 1451 through 1600 a.d. History of medicine, 15th cent. And history of medicine, 16th cent. Are also available.
(12 Dec 1998)
immediate early gene Class of genes whose expression is low or undetectable in quiescent cells, but whose transcription is activated within minutes after extracellular stimulation such as addition of a growth factor. C fos and c myc proto-oncogenes were among the first IEG's to be identified. Many IEG's encode transcription factors and therefore have a regulatory function.
(18 Nov 1997)
immediate-early proteins Proteins that are coded by immediate-early genes, in the absence of de novo protein synthesis. The term was originally used exclusively for viral regulatory proteins that were synthesised just after viral integration into the host cell. It is also used to describe cellular proteins which are synthesised immediately after the resting cell is stimulated by extracellular signals.
(12 Dec 1998)
early 1. In advance of the usual or appointed time; in good season; prior in time; among or near the first; opposed to late; as, the early bird; an early spring; early fruit. "Early and provident fear is the mother of safety." (Burke) "The doorsteps and threshold with the early grass springing up about them." (Hawthorne)
2. Coming in the first part of a period of time, or among the first of successive acts, events, etc. "Seen in life's early morning sky." (Keble) "The forms of its earlier manhood." (Longfellow) "The earliest poem he composed was in his seventeenth summer." (J. C.
<philosophy> Shairp) Early English See the Note under English. Early English architecture, the first of the pointed or Gothic styles used in England, succeeding the Norman style in the 12th and 13th centuries.
Synonym: Forward, timely, not late, seasonable.
Origin: OE. Earlich. See Early.
Source: Websters Dictionary
(01 Mar 1998)
early ambulation Procedure characterised by a shorter period of hospitalization or recumbency or by more rapid mobilization than is normally practiced.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Early Growth Response Protein 3 - »õâ An early growth response transcription factor that is essential for the development of MUSCLE SPINDLES.
    Synonyms : EGR3 Transcription Factor, Early Growth Response Transcription Factor 3, Transcription Factor, EGR3
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • protein
    ´Ü¹éÁú
  • coat protein
    ÇǸ· ´Ü¹é
  • conjugated protein
    º¹ÇÕ ´Ü¹éÁú
  • fish protein concentrate
    ¾îÀ° ³óÃà ´Ü¹é
  • protein
    ´Ü¹éÁú;´Ü¹éÁúÀÇ(À» ÇÔÀ¯ÇÏ´Â). proteinic a.
  • protein clock
    ´Ü¹éÁú ½Ã°è(´Ü¹éÁú ÁøÈ­ ¼Óµµ¸¦ Á¶ÀýÇÏ´Â °¡¼³Àû ü³» ±â±¸)
  • repressor protein
    ¾ïÁ¦ ´Ü¹é(Á¦¾î À¯ÀüÀÚ¿¡ ÀÇÇÏ¿© ¸¸µé¾îÁö´Â ´Ü¹é)
  • growth
    ¼ºÀå,¹ß´Þ,Áõ°¡
  • response
    ÀÀ´ä
  • conditioned reflex (response)
    Á¶°Ç ¹Ý»ç
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • flexible response
    ½ÅÃàÀû ´ëÀÀ(1967³â NOTO°¡ ¹Ù¸£»þ¹Ù Á¶¾à±º¿¡ ´ëÇØ¼­ äåÇÑ Àü·«)
  • flexible response
    ½ÅÃàÀû´ëÀÀ
  • frequency response
    Á֯ļöÀÀ´ä
  • galvanic skin response
    Àü±â ÇǺΠ¹ÝÀÀ(°ÅÁþ¸» ŽÁö±â¿¡ ÀÀ¿ë)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á